Form 4: Cue Biopharma SVP, General Counsel Colin Sandercock Reports Stock Option Grant

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Summary

• On March 6, 2024, Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., was granted stock options to purchase 175,000 shares of common stock at an exercise price of $1.94.
• The options vest in eight equal semi-annual installments starting September 6, 2024, and expire on March 5, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The grant of options can be seen as a positive sign of aligning management interests with shareholders.

Positives

• The grant of stock options aligns the interests of the executive with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and the vesting schedule are typical for executives at Sandercock's level.
• Comparable companies such as Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates